- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Auricular percutaneous neurostimulation, Sham percutaneous neurostimulation
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 4 Years to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 5,778
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Interventions
- Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma
- Interventions
- PEEL-224, Temozolomide, Vincristine, Pegfilgrastim, Filgrastim
- Drug · Biological
- Lead sponsor
- David S Shulman, MD
- Other
- Eligibility
- 12 Years to 49 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Nausea, Vomiting, Terminally Ill
- Interventions
- Palonosetron
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Interventions
- Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide
- Drug
- Lead sponsor
- Paolo Caimi, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Radiation and chemoradiation, Radical cystectomy
- Radiation · Procedure
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Opioid-use Disorder
- Interventions
- Contingency Management, Brief Motivational Interviewing + Substance Free Activities + Mindfulness
- Behavioral
- Lead sponsor
- Karen Derefinko, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Metastases
- Interventions
- Questionnaires, Medical Record Review
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Depressive Symptoms, Cognitive Symptom
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 30 Years to 55 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Respiratory Infections
- Interventions
- Release of test results
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- CRS-207, Pembrolizumab
- Biological
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Neoplasm, Colorectal
- Interventions
- Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan, Bevacizumab, 5-FU
- Drug · Biological
- Lead sponsor
- NuCana plc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 16
- States / cities
- Newark, Delaware • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- Treatment Planning using the DIBH Technique
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Lymphoma
- Interventions
- Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more
- Conditions
- ADHD
- Interventions
- Partnering to Achieve School Success (PASS), Treatment as Usual (TAU)
- Behavioral · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma
- Interventions
- Total consolidative MPDT
- Procedure
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dry Eye, Ocular Surface Disease, Cataract Surgery, Eyes Dry Feeling of
- Interventions
- Lacrifill, Saline
- Drug
- Lead sponsor
- Eye Research Associates, LLC
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Pittsburg, Kansas • Kansas City, Missouri
- Conditions
- Depression - Major Depressive Disorder
- Interventions
- Approach-Avoidance Decision-Making Task
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Brain Cancer, Brain Stem Glioma
- Interventions
- Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy
- Drug · Radiation
- Lead sponsor
- Y-mAbs Therapeutics
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
- Interventions
- Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • Somerset, New Jersey
- Conditions
- Facial Flushing
- Interventions
- botulinum toxin A, Saline Control
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fear of Heights, Acrophobia, Specific Phobia, Anxiety Disorder
- Interventions
- Exposure Therapy (In Vivo), Exposure Therapy (Virtual Reality)
- Behavioral
- Lead sponsor
- University of Notre Dame
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Notre Dame, Indiana
- Conditions
- Vascular Anomalies
- Interventions
- Marimastat
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
- Interventions
- Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Bay Shore, New York • Kettering, Ohio • Memphis, Tennessee + 1 more